Taking AIM at Breast Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04720209 |
Recruitment Status :
Recruiting
First Posted : January 22, 2021
Last Update Posted : January 23, 2024
|
Tracking Information | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
First Submitted Date ICMJE | January 19, 2021 | ||||||||||||||
First Posted Date ICMJE | January 22, 2021 | ||||||||||||||
Last Update Posted Date | January 23, 2024 | ||||||||||||||
Actual Study Start Date ICMJE | August 13, 2021 | ||||||||||||||
Estimated Primary Completion Date | June 15, 2025 (Final data collection date for primary outcome measure) | ||||||||||||||
Current Primary Outcome Measures ICMJE |
|
||||||||||||||
Original Primary Outcome Measures ICMJE |
Decrease in adipose tissue levels of inflammation. [ Time Frame: 16 Weeks ] Adipose tissue inflammation will be assessed by measuring: M1, M2, ATMs, and adipose tissue secretion levels of inflammatory cytokines secreted. Measuring blood biomarkers related to WAT inflammation will assess systemic inflammation: leptin, adiponectin, TNF-a, IL6, IL-8, hsCR
|
||||||||||||||
Change History | |||||||||||||||
Current Secondary Outcome Measures ICMJE |
4-month CARE intervention on sarcopenic obesity. [ Time Frame: 16 Weeks ] sarcopenic obesity will be assessed via dual energy X-ray absorptiometry using a validated equation.
|
||||||||||||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||||||||||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||||||||||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||||||||||||
Descriptive Information | |||||||||||||||
Brief Title ICMJE | Taking AIM at Breast Cancer | ||||||||||||||
Official Title ICMJE | Taking AIM at Breast Cancer: Targeting Adiposity and Inflammation With Movement to Improve Prognosis in Breast Cancer Survivors | ||||||||||||||
Brief Summary | The purpose of this research is to determine whether a 16-week exercise program for individuals with breast cancer and have completed treatment (i.e., surgery, chemotherapy, or radiation) for breast cancer will decrease inflammation in fat tissue. | ||||||||||||||
Detailed Description | This study is about using different types of exercise to reduce inflammation in fat tissue in an effort to minimize the risk of cancer recurrence related to being overweight or obese. The investigators hope to learn whether participating in a specific exercise program can cause inflammation in the fat tissue to decrease. The names of the study interventions involved in this study are:
The research study procedures include screening for eligibility, and study treatment including evaluations and follow up visits. The study treatment will be for 4 months and participants will followed for 8 months. The total time for participation in this study will be about 12 months. It is expected that about 300 people will take part in this research study. |
||||||||||||||
Study Type ICMJE | Interventional | ||||||||||||||
Study Phase ICMJE | Not Applicable | ||||||||||||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Prevention |
||||||||||||||
Condition ICMJE |
|
||||||||||||||
Intervention ICMJE |
|
||||||||||||||
Study Arms ICMJE |
|
||||||||||||||
Publications * | Not Provided | ||||||||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||||||||
Recruitment Information | |||||||||||||||
Recruitment Status ICMJE | Recruiting | ||||||||||||||
Estimated Enrollment ICMJE |
300 | ||||||||||||||
Original Estimated Enrollment ICMJE | Same as current | ||||||||||||||
Estimated Study Completion Date ICMJE | June 15, 2026 | ||||||||||||||
Estimated Primary Completion Date | June 15, 2025 (Final data collection date for primary outcome measure) | ||||||||||||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||||||||||||
Sex/Gender ICMJE |
|
||||||||||||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||||||||||||
Accepts Healthy Volunteers ICMJE | No | ||||||||||||||
Contacts ICMJE |
|
||||||||||||||
Listed Location Countries ICMJE | United States | ||||||||||||||
Removed Location Countries | |||||||||||||||
Administrative Information | |||||||||||||||
NCT Number ICMJE | NCT04720209 | ||||||||||||||
Other Study ID Numbers ICMJE | 20-172 | ||||||||||||||
Has Data Monitoring Committee | No | ||||||||||||||
U.S. FDA-regulated Product |
|
||||||||||||||
IPD Sharing Statement ICMJE |
|
||||||||||||||
Current Responsible Party | Christina Dieli-Conwright, PhD, Dana-Farber Cancer Institute | ||||||||||||||
Original Responsible Party | Same as current | ||||||||||||||
Current Study Sponsor ICMJE | Dana-Farber Cancer Institute | ||||||||||||||
Original Study Sponsor ICMJE | Same as current | ||||||||||||||
Collaborators ICMJE | National Cancer Institute (NCI) | ||||||||||||||
Investigators ICMJE |
|
||||||||||||||
PRS Account | Dana-Farber Cancer Institute | ||||||||||||||
Verification Date | January 2024 | ||||||||||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |